Syndicate content World Pharma News
World Pharma News - one of the world's leading web-based pharmaceutical news publications - is committed to providing and disseminating the most prominent pharmaceutical news and achievements
Updated: 2 years 24 weeks ago

FDA approves novel preventive treatment for migraine

Fri, 05/18/2018 - 10:00
The U.S. Food and Drug Administration today approved Aimovig (erenumab-aooe) for the preventive treatment of migraine in adults. The treatment is given by once-monthly self-injections. Aimovig is the first FDA-approved preventive migraine treatment in a new class of drugs that work by blocking the activity of calcitonin gene-related peptide, a molecule that is involved in migraine attacks.
Categories: Category 2

Doctors in US and Canada launch sweeping pharmaceutical reform proposal

Thu, 05/17/2018 - 12:00
The skyrocketing cost of prescription drugs is one of the biggest concerns for American voters. However, in his proposal last Friday, President Donald Trump failed to offer any new policies that would expand access, reduce costs, or increase the safety and efficacy of prescriptions. Today, a group of 21 prominent physicians published a comprehensive proposal to ensure universal access to safe, innovative, and affordable medications.
Categories: Category 2

SMi presents the launch of Cell & Gene Therapy 2018

Thu, 05/17/2018 - 10:00
10 - 11 October, London, UK.
SMi introduces their inaugural event on Cell & Gene Therapy which takes place between the 10th and 11th October 2018, with an interactive pre-conference workshop on the 9th October. Cell and gene therapeutics have revolutionised modern medicine and mark a new generation in biomedical and agricultural sciences. The latest developments in cell and gene therapies and specifically in gene editing, technologies present unlimited research opportunities ranging from novel therapeutic tools to a potential revolution in the field of drug discovery.
Categories: Category 2

Stroke prevention drug combo shows promise

Wed, 05/16/2018 - 12:00
If you've had a minor stroke or a transient ischemic stroke (TIA), taking the clot-preventing drug clopidogrel along with aspirin may lower your risk of having a major stroke within the next 90 days, according to new research published in The New England Journal of Medicine.
Categories: Category 2

Novo Nordisk increases commitment to stem cell-based therapies

Wed, 05/16/2018 - 10:00
Novo Nordisk today announced an increased commitment to stem cell-based therapies and an expansion of the focus on type 1 diabetes into other serious chronic diseases. This has been made possible through an exclusive collaboration with the University of California San Francisco (UCSF) in which a first milestone in the development of human embryonic stem cell lines has been reached.
Categories: Category 2

FDA approves first epoetin alfa biosimilar for the treatment of anemia

Tue, 05/15/2018 - 12:00
The U.S. Food and Drug Administration today approved Retacrit (epoetin alfa-epbx) as a biosimilar to Epogen/Procrit (epoetin alfa) for the treatment of anemia caused by chronic kidney disease, chemotherapy, or use of zidovudine in patients with HIV infection. Retacrit is also approved for use before and after surgery to reduce the chance that red blood cell transfusions will be needed because of blood loss during surgery.
Categories: Category 2

First clues to the causes of multiple sclerosis

Tue, 05/15/2018 - 10:00
Multiple sclerosis, which affects 1 in 1,000 people, is frequently characterised by relapses associated with variable functional impairments including among others vision problems, impairment of locomotor functions or difficulties with speech. There is still no cure for multiple sclerosis, with current treatments largely based on managing symptoms, especially accelerating recovery phases following a relapse and reducing the number and severity of relapses.
Categories: Category 2

Sanofi and Ablynx announce the successful results of the initial tender offer period

Mon, 05/14/2018 - 12:00
Sanofi (Euronext: SAN; NYSE: SNY) and Ablynx (Euronext Brussels and Nasdaq: ABLX) today announced the results of the initial tender offer period of Sanofi's previously announced tender offers to acquire all of the outstanding shares (including shares represented by American Depositary Shares ("ADSs")), warrants and convertible bonds (together, the "Securities") of Ablynx.
Categories: Category 2

Tumor-like spheres help scientists discover smarter cancer drugs

Mon, 05/14/2018 - 10:00
Cancer is a disease often driven by mutations in genes. As researchers learn more about these genes, and the proteins they code for, they are seeking smarter drugs to target them. The ultimate goal is to find ways to stop cancer cells from multiplying out of control, thereby blocking the growth and spread of tumors.
Categories: Category 2

AstraZeneca provides update on GALATHEA Phase III trial for Fasenra in chronic obstructive pulmonary disease

Fri, 05/11/2018 - 12:00
AstraZeneca and MedImmune, its global biologics research and development arm, today announced top-line results from the GALATHEA Phase III trial for Fasenra (benralizumab) in patients with moderate to very severe chronic obstructive pulmonary disease (COPD). The trial did not meet the primary endpoint of a statistically-significant reduction of exacerbations in patients with COPD.
Categories: Category 2

FDA expands approval of Gilenya to treat multiple sclerosis in pediatric patients

Fri, 05/11/2018 - 10:00
The U.S. Food and Drug Administration today approved Gilenya (fingolimod) to treat relapsing multiple sclerosis (MS) in children and adolescents age 10 years and older. This is the first FDA approval of a drug to treat MS in pediatric patients.
Categories: Category 2

Research suggests a 15-minute 'daily mile' could enhance health of the world's children

Thu, 05/10/2018 - 12:00
Policymakers should consider introducing The Daily Mile to improve the health and fitness of schoolchildren around the world, according to new research led by the Universities of Stirling and Edinburgh. The first study of the popular Daily Mile initiative - which involves children taking a 15-minute break from class to do physical activity - has confirmed it improves fitness, body composition and activity levels in participants.
Categories: Category 2

Alcon Cares Project 100 commits to reducing cataract blindness globally

Thu, 05/10/2018 - 10:00
Alcon, the global leader in eye care and a division of Novartis, has announced Alcon Cares Project 100, which aims to reduce cataract blindness by providing equipment to perform phaco surgeries. Alcon Cares, a foundation that oversees equipment and product donations to those in need, will give 100 reprocessed Infiniti units to eligible clinics in Asia, Central and South America, and Africa over the next three years, making it one of the largest eye care equipment donations of its kind.
Categories: Category 2

Applied science may yield more translational research publications than basic science

Wed, 05/09/2018 - 12:00
While translational research can happen at any stage of the research process, a recent investigation of behavioral and social science research awards granted by the NIH between 2008 and 2014 revealed that applied science yielded a higher volume of translational research publications than basic science, according to a study published May in the open-access journal PLOS ONE
Categories: Category 2

New cancer immunotherapy drugs rapidly reach patients after approval

Wed, 05/09/2018 - 10:00
The majority of patients eligible for cancer immunotherapy drugs known as checkpoint inhibitors received treatment within a few months of FDA approval, according to a new Yale-led study. The finding suggests that cancer immunotherapies are adopted at a much quicker pace than is typical for newly approved medical treatments, the researchers said.
Categories: Category 2

FDA grants priority review to Roche's cancer immunotherapy TECENTRIQ (atezolizumab) for initial treatment of people with a specific type of metastatic lung cancer

Tue, 05/08/2018 - 12:00
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the US Food and Drug Administration (FDA) has accepted the company's supplemental Biologics License Application (sBLA) and granted Priority Review for TECENTRIQ® (atezolizumab), in combination with Avastin® (bevacizumab), paclitaxel and carboplatin (chemotherapy), for the initial (first-line) treatment of people with metastatic non-squamous non-small cell lung cancer (NSCLC).
Categories: Category 2

Hypertensive patients may benefit from folic acid supplements

Tue, 05/08/2018 - 10:00
Hypertensive adults with low platelet count who took a combined daily pill of both enalapril and folic acid saw a 73 percent reduction in their risk of first stroke compared to patients who took only enalapril daily, according to a study published in the Journal of the American College of Cardiology.
Categories: Category 2

Chemical octopus catches sneaky cancer clues, trace glycoproteins

Mon, 05/07/2018 - 12:00
Cancer drops sparse chemical hints of its presence early on, but unfortunately, many of them are in a class of biochemicals that could not be detected thoroughly, until now. Researchers at the Georgia Institute of Technology have engineered a chemical trap that exhaustively catches what are called glycoproteins, including minuscule traces that have previously escaped detection.
Categories: Category 2

AstraZeneca and Luye Pharma Group enter agreement for rights to Seroquel and Seroquel XR in the UK, China and other international markets

Mon, 05/07/2018 - 10:00
AstraZeneca has entered into an agreement with Luye Pharma Group, Ltd. (Luye Pharma) for the sale and licence of the rights to Seroquel and Seroquel XR in the UK, China and other international markets, including Brazil, Australia, Saudi Arabia, Mexico, South Korea, Thailand, Argentina, Malaysia and South Africa.
Categories: Category 2

To treat pain, you need to treat the patient

Fri, 05/04/2018 - 10:00
People in chronic pain are some of the most difficult patients to treat. They have complex circumstances that medicine can't always remedy. Pain can be amplified, by depression and anxiety, genetics and quality of life. Genetics can also play a role in how people experience pain. Physicians are less prone to prescribe opioid medication to patients with long-term pain - but they need more treatment options.
Categories: Category 2
  • Professionalism.
    We are specialists in this field and like our activity, so we can guarantee the quality of our work.
  • Competitiveness.
    Individual solutions for a competitive price.
  • Confidentiality.
    We appreciate the cooperation, maintain confidentiality and seek for a long-term partnership